News Alert: ViroPharma reinforces commitment to address medical needs and provide innovative treatment options for patients with adrenal insufficiency at ECE

Maidenhead, England (ots/PRNewswire) -

Who: ViroPharma, an international biopharmaceutical company
committed to developing and commercialising innovative solutions for
physicians to address the unmet medical needs of patients living with
diseases that have few, if any, clinical therapeutic options.

What: European Congress of Endocrinology, Bella Center,
Copenhagen, Denmark, 27 April - 1 May

- The ViroPharma symposium, 'A new paradigm in the treatment of patients
with adrenal insufficiency', 28 April 2013, 18.30-20.00, Auditorium 15, will bring
together an internationally renowned faculty to discuss:
- Challenges of meeting needs of adrenal insufficiency (AI) patients with
immediate release hydrocortisone
- The impact of current therapies on well-being and quality of life
- Latest research on the circadian rhythm of cortisol, including its
importance in metabolism and cardiovascular health
- Innovative new approaches for optimising the management of AI
- Two posters will be presented at the ECE scientific sessions:
- Poster 1: European Adrenal Insufficiency Registry (EU-AIR): a comparative
observational study of glucocorticoid replacement therapy. Poster P49. Ekman et
al.: Tuesday 30 April, 13:00-14:00 PDT, Poster hall.
- Poster 2: Management of Addison's disease patients using dual release
hydrocortisone during periods of intercurrent illness (ICI). Poster P24.
Johannsson et al.: Monday 29 April, 13:00:14:00 PDT, Poster hall.

Symposium faculty:

Co-Chairs: Eystein Husebye, Bergen, Norway; Ulla Feldt-Rasmussen,

Copenhagen, Denmark

Panel: Eve Van Cauter, Chicago, USA; Ashley Grossman, Oxford, UK;
Anna

Nilsson, Gothenburg, Sweden; Marcus Quinkler, Berlin, Germany

For further information about ViroPharma, visit
http://www.viropharma.com

For further information about ECE, visit http://www.ece2013.org

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical
company committed to developing and commercializing novel solutions
for physician specialists to address unmet medical needs of patients
living with diseases that have few if any clinical therapeutic
options, including C1 esterase inhibitor deficiency, treatment of
prolonged, acute, convulsive seizures in children and adolescents,
adrenal insufficiency, and C. difficile infection (CDI). Our goal is
to provide rewarding careers to employees, to create new standards of
care in the way serious diseases are treated, and to build
international partnerships with the patients, advocates, and health
care professionals we serve.

ots Originaltext: ViroPharma Incorporated
Im Internet recherchierbar: http://www.presseportal.de

Contact:
ViroPharma Incorporated Contacts:
Emma White (Media), PR & Advocacy Manager, Europe,
Phone +44-(0)7881-534-541